Magdalen Scientific Hosts Groundbreaking iwGPRC5D Meeting in New York

IME EDITORIAL BOARD SUPPORTERS INFORMATION INSIGHTS JOIN OUR TEAM CONTACT US

25 March 2025

Last month, Magdalen Scientific hosted the inaugural International Workshop on GPRC5D-targeted Therapies (iwGPRC5D) in New York, bringing together a global community of leading clinical and translational researchers in the field of multiple myeloma.

This landmark event featured a full day of dynamic presentations and thought-provoking discussions, focused on the latest developments in GPRC5D-targeted therapies. The workshop provided an invaluable forum for sharing cutting-edge insights and fostering collaboration in a space that is rapidly shaping the future of myeloma treatment.

Chaired by Professor Saad Usmani and Professor Sham Mailankody, the meeting featured a distinguished faculty of international experts. Sessions spanned the full spectrum of research and clinical practice—from basic and pre-clinical science to translational advances, clinical trial updates, and the real-world application of GPRC5D-targeted therapies.

The concept for the iwGPRC5D meeting was conceived by Professor Saad Usmani and the Myeloma faculty during Magdalen Scientific’s International Workshop on High-Risk Multiple Myeloma in October 2024. Recognizing the urgency and momentum in this area of research, the iwGPRC5D scientific committee and Magdalen Scientific team rapidly mobilized to bring this important initiative to life in under three months.

Healthcare professionals are invited to access the presentations from the inaugural iwGPRC5D meeting, now available to view online [ https://www.vjhemonc.com/event/iwgprc5d-2025/ ]. These expert-led sessions provide deep insights into the evolving science and clinical landscape of GPRC5D-targeted therapies in multiple myeloma.

In addition to the main program, Magdalen Scientific captured a series of expert roundtable discussions onsite, specifically developed to support clinicians in optimizing treatment strategies and effectively managing toxicities associated with GPRC5D-targeted therapies.

These educational roundtables cover key areas essential to clinical practice, including:

GPRC5D as a Target & Mechanisms of Resistance
Targeting GPRC5D: Clinical and Real-World Evidence
Practical Considerations and Management Strategies with GPRC5D-Targeted Therapies

These roundtables will be available for healthcare professionals to view on VJHemOnc soon.

The success of the iwGPRC5D meeting would not have been possible without the generous support of our industry supporters. We extend our sincere thanks to Johnson & Johnson, a platinum sponsor of the workshop, and to Bristol Myers Squibb for their educational grant, which enabled the development of the roundtable content for clinicians.

At Magdalen Scientific, we are committed to fostering meaningful dialogue and collaboration across the global HCP community. We welcome support from industry to provide clinicians with a unique opportunity to be brought together to facilitate interactive and stimulating discussion and debates to help improve patient outcomes.

To learn more about our upcoming scientific workshops, please visit: https://magdalenscientific.com/workshops/

Back to MMP Insights